Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anthem BiosciencesNSE:ANTHEM -0.93%34 Pretax Margin % is 45.49% as of Mar. 2026, which is 17% above its 10-year median of 38.80. GuruFocus rates NSE:ANTHEM with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 941 Biotechnology companies, Anthem Biosciences ranks better than 92.67% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Anthem Biosciences Pretax Margin % Related Terms
Anthem Biosciences Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Anthem Biosciences's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ANTHEM vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Anthem Biosciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anthem Biosciences Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anthem Biosciences's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Anthem Biosciences's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anthem Biosciences (NSE:ANTHEM) has a Pretax Margin % of 45.49% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Anthem Biosciences and its competitors. This is 17% above median its historical median of 38.80. Over the past decade, Anthem Biosciences' Pretax Margin % has ranged from 33.63 to 47.05. According to the industry distribution chart, Anthem Biosciences ranks #69 out of 941 companies in the Biotechnology industry, placing it in the top 7.3%.
Is Anthem Biosciences' Pretax Margin % too high?
Anthem Biosciences' current Pretax Margin % of 45.49% is 17% above median its 10-year median of 38.80. Over the past 10 years, this metric has ranged from a low of 33.63 to a high of 47.05. Based on the distribution chart, Anthem Biosciences ranks #69 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Anthem Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Anthem Biosciences' Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anthem Biosciences ranks #69 out of 941 companies for Pretax Margin %. This places Anthem Biosciences in the top 7% of its industry — outperforming the majority of peers. Historically, Anthem Biosciences' own Pretax Margin % has ranged from 33.63 to 47.05 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Anthem Biosciences and its competitors. Anthem Biosciences's current Pretax Margin % is 45.49%, which is 17% above median its own 10-year median of 38.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthem Biosciences stock overvalued right now?
Anthem Biosciences (NSE:ANTHEM) has a current Pretax Margin % of 45.49%. The current Pretax Margin % is 45.49%, which is 17% above median its 10-year median of 38.80. Anthem Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Anthem Biosciences (NSE:ANTHEM), the current Pretax Margin % is 45.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
34GF Score
Get the complete analysis for NSE:ANTHEM
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ANTHEM has been successfully added to your 
